title: Central nervous system lymphoma in immunocompetent patients: the North Shore-Long Island Jewish Health System experience.
abstract: Of the 74 immunocompetent patients diagnosed between July 2004 and June 2011 at the North Shore University Hospital and Long Island Jewish Medical Center with primary central nervous system lymphoma, 71 (95.9%) had diffuse large B-cell lymphomas (DLBCL). The median patient age was 68 years (range: 19-87 years) with a slight male preponderance (1.1:1). The overall median survival time was 21 months. For patients older than 70 years, the median survival time was 8 months while for those 70 years or younger, the median survival time was 27 months (p<0.01). Female patients had a worse prognosis than male patients (p<0.05, median survival time, 17 months compared to 23 months). We had enough data from 52 of these 71 patients to define the lymphomas as either germinal center B-cell-like (GCB) or activated B-cell-like (ABC) DLBCL. Of these 52 patients, 42 (80.8%) had ABC DLBCL while only 10 (19.2%) had GCB DLBCL. The patients in the GCB subgroup seemed to survive longer than the patients in the ABC subgroup, although the difference did not reach statistical significance. No statistically significant difference in overall survival was seen between patients with BCL-6 positive or negative DLBCL; or between patients with BCL-2 positive or negative DLBCL.
authors.affiliation: Department of Pathology and Laboratory Medicine, North Shore-Long Island Jewish Health System, Hofstra North Shore-LIJ School of Medicine, Lake Success, NY 11042, USA.
authors.forename: Xinmin
authors.initials: X
authors.lastname: Zhang
authors.forename: Qiang Hua
authors.initials: QH
authors.lastname: Chen
authors.forename: Peter
authors.initials: P
authors.lastname: Farmer
authors.forename: Mansoor
authors.initials: M
authors.lastname: Nasim
authors.forename: Alexis
authors.initials: A
authors.lastname: Demopoulos
authors.forename: Craig
authors.initials: C
authors.lastname: Devoe
authors.forename: Tulika
authors.initials: T
authors.lastname: Ranjan
authors.forename: Mark B
authors.initials: MB
authors.lastname: Eisenberg
authors.forename: Michael
authors.initials: M
authors.lastname: Schulder
authors.forename: Chengpeng
authors.initials: C
authors.lastname: Bi
authors.forename: Jian Yi
authors.initials: JY
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016543:Central Nervous System Neoplasms / Q000453:epidemiology* / Q000208:ethnology* / Q000401:mortality; D004268:DNA-Binding Proteins / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D007121:Immunocompetence; D007585:Jews; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000453:epidemiology* / Q000208:ethnology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000378:metabolism; D009519:New York City / Q000453:epidemiology / Q000208:ethnology; D051560:Proto-Oncogene Proteins c-bcl-6; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: C084103:BCL6 protein, human; D004268:DNA-Binding Proteins; D051560:Proto-Oncogene Proteins c-bcl-6; D015260:Neprilysin